51st week of 2015 patent applcation highlights part 20 |
Patent application number | Title | Published |
20150361069 | QUINAZOLINES AS KINASE INHIBITORS - Disclosed are compounds that are inhibitors of RIP2 kinase and methods of making and using the same. | 2015-12-17 |
20150361070 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present application provides the compounds of formula (J), | 2015-12-17 |
20150361071 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present application provides the compounds of formula (J), | 2015-12-17 |
20150361072 | PYRIDINE DERIVATIVES AS SOFT ROCK INHIBITORS - The present invention relates to new kinase inhibitors of Formula (I) or a stereoisomer, tautomer, racemic, salt, hydrate, or solvate thereof, and more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Respiratory and Gastro-Intestinal diseases. | 2015-12-17 |
20150361073 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS - The present disclosure provides processes for the preparation of a compound of formula: | 2015-12-17 |
20150361074 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY - A compound of the formula: (I) or a pharmaceutically acceptable salt thereof, wherein: L is a 5-membered nitrogen-containing heteroaryl which is optionally fused to a benzene; Y is a 5, 6 or 7-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene; and W is a zinc-binding group. The compounds are HDAC inhibitors and therefore have potential utility in therapy. | 2015-12-17 |
20150361075 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2015-12-17 |
20150361076 | OXIDATIVE DEAROMATIZATION OF BERBINES - The present disclosure provides oxidized berbine derivatives, processes for their preparation, and methods of using the oxidized berbine derivatives. | 2015-12-17 |
20150361077 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY - Amine compounds having activity against inflammation, fungi, unicellular parasitic microorganisms, and cancer are described. The compounds contain a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms. | 2015-12-17 |
20150361078 | Imidazopyridine Compounds and Uses Thereof - This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes. | 2015-12-17 |
20150361079 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 - The present invention relates to novel spiro-quinazolinone derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling. | 2015-12-17 |
20150361080 | SUBSTITUTED NORIBOGAINE - This invention relates noribogaine derivatives, compositions and methods of use thereof. | 2015-12-17 |
20150361081 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 - Described are negative allosteric modulators of metabotropic glutamate receptor 3 (mGlu | 2015-12-17 |
20150361082 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS - The present invention relates to novel compounds that inhibit Lp-PLA | 2015-12-17 |
20150361083 | NOVEL SELECTIVE PI3K DELTA INHIBITORS - The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them. | 2015-12-17 |
20150361084 | Morphine Sulfate Methanolic Solvate, Processes for Making Same and Related Compositions and Methods for Treating Pain - Processes for reducing the amount of impurities, especially α,β-unsaturated ketones (ABUK), in materials containing morphine. Novel compounds, namely low ABUK morphine sulfate methanolic solvate, and a novel crystal form are also described. The method for making morphine sulfate methanolic solvate comprises mixing a morphine free base composition with methanol to form a solution and adding a liquid comprising sulfuric acid to the solution to form a morphine sulfate methanolic solvate precipitate. A method of making a morphine sulfate compound comprises drying the morphine sulfate methanolic solvate in the presence of water vapor, such that methanol molecules are removed and replaced with water vapor molecules. A composition for treating pain comprises the morphine sulfate compound and at least one pharmaceutically acceptable excipient. A method for treating pain comprises administering to a patient in need thereof the composition comprising the morphine sulfate compound and at least one pharmaceutically acceptable excipient. | 2015-12-17 |
20150361085 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: | 2015-12-17 |
20150361086 | HIGH-FLUIDITY NON-CAKING DIANHYDROHEXITOL PELLETS - Dianhydrohexitol pellets, whose fluidity is preserved even after lengthy storage, include between 90% and 100%, preferably between 95% and 100%, and more preferentially between 97% and 100% of dianhydrohexitols by weight, on a dry weight basis, and have the particularity of not being subject to caking. A process for preparing the dianhydrohexitol pellets is also described. | 2015-12-17 |
20150361087 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 2015-12-17 |
20150361088 | TWO-CARBON LINKED ARTEMISININ-DERIVED TRIOXANE DIMERS - Two-carbon linked artemisinin-derived trioxane dimers and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer. | 2015-12-17 |
20150361089 | FUNCTIONALIZED GRAPHENE OXIDE AND METHODS OF PRODUCING THE SAME - A functionalized graphene composition, doped-reduced graphene oxide and methods of producing the same are provided. The method of producing doped-reduced graphene oxide involves a step of dispersing a graphene oxide in an organic solvent, and a step of adding BF3-etherate, and alkylthiol, arylthiol, alkylamine, or arylamine to the organic solvent in which the graphene oxide is dispersed to obtain a fluorine doped-reduced graphene oxide. | 2015-12-17 |
20150361090 | NOVEL LABELED CHEMICALLY REACTIVE AND BIOLOGICALLY ACTIVE COMJUGATES, AND METHODS AND COMPOSITIONS THEREOF - The invention generally relates to novel fluorophore-labeled, bi- or multi-functional, chemically reactive and/or biologically active conjugates, and related compositions and methods thereof. | 2015-12-17 |
20150361091 | OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF - The present invention relates to the field of a pharmaceutical compound, and more specifically, relates to a new oxazolidone compound, an enantiomer, a diastereoisomer and a raceme thereof, and a mixture thereof, and a pharmaceutically acceptable salt thereof, a preparation method thereof, an application thereof as a bioactive substance in a drug. The compound in the present invention has strong anticoagulant activity, does not affect the activity of thrombin, and can reduce the risk of hemorrhage. A pharmacokinetics experiment shows that the compound in the present invention further has good metabolic characteristics, and has a far better oral bioavailability than a positive contrastive agent rivaroxaban. | 2015-12-17 |
20150361092 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 - The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them. | 2015-12-17 |
20150361093 | HIV REPLICATION INHIBITOR - The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. | 2015-12-17 |
20150361094 | BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS - This application relates to derivatives of Formula I: | 2015-12-17 |
20150361095 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present application provides the compounds of formula (J), | 2015-12-17 |
20150361096 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS - The invention relates to heterocyclic amide derivatives of formula (I), | 2015-12-17 |
20150361097 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS - The invention relates to heterocyclic amide derivatives of formula (I), | 2015-12-17 |
20150361098 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES - Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions. | 2015-12-17 |
20150361099 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES - Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively | 2015-12-17 |
20150361100 | INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS - Compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with PI3K enzymes. | 2015-12-17 |
20150361101 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C - The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 2015-12-17 |
20150361102 | METHOD FOR PRODUCING METAL COMPLEX - Disclosed is a method for producing a metal complex comprising a multivalent carboxylic acid compound, at least one metal ion, an organic ligand capable of multidentate binding to the metal ion, and a monocarboxylic acid compound, wherein the metal ion is used in the form of a metal salt having a counter anion of the metal ion, a conjugate acid of the counter anion having a first dissociation exponent larger by 0 to 6 than that of the multivalent carboxylic acid compound, and at least one of the multivalent carboxylic acid compound, the metal ion, the organic ligand capable of multidentate binding, and the monocarboxylic acid compound is reacted in a suspended state. This method can effectively produce a metal complex. | 2015-12-17 |
20150361103 | REACTION ACCELERATOR FOR A COPOLYMERISATION, ELECTRICAL-INSULATION TAPE, ELECTRICAL-INSULATION BODY, AND CONSOLIDATION BODY - A compound having the structural formula R | 2015-12-17 |
20150361104 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS - This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 2015-12-17 |
20150361105 | PROTEASOME INHIBITORS - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2015-12-17 |
20150361106 | BETA-LACTAMASE INHIBITORS - Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. | 2015-12-17 |
20150361107 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS - Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections. | 2015-12-17 |
20150361108 | ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS - Described herein are compounds and compositions that modulate the activity of beta-lactamases and methods thereof. In some embodiments, the compounds described herein are biologically hydrolyzed to a beta-lactamase inhibitor. In certain embodiments, the compounds described herein are useful for the treatment of bacterial infections. | 2015-12-17 |
20150361109 | METHODS FOR PRODUCING BORYLATED ARENES - Methods for the borylation of aromatic compounds using cobalt catalysts are provided. | 2015-12-17 |
20150361110 | SUPER LEWIS ACIDIC BORATE ESTERS AS 18F-LABELED PET PROBES - Compounds having a 1-bora-1-fluoro-2,6,7-trioxabicyclo[2.2.2]octane moiety wherein the fluorine is | 2015-12-17 |
20150361111 | Catalytic method for obtaining substituted (triorganosilyl)alkynes and their derivatives - New (triorganosilyl)alkynes and their derivatives having general formula R | 2015-12-17 |
20150361112 | PLATINUM CATALYZED HYDROSILYLATION REACTIONS UTILIZING CYCLODIENE ADDITIVES - A process for the hydrosilylation of an unsaturated compound comprising reacting (a) a silyl hydride with (b) an unsaturated compound in the presence of (c) a platinum compound and (d) a cyclodiene, with the provisos that (i) when the unsaturated compound is a terminal alkyne, the silyl hydride is other than a halosilane, and (ii) when the platinum compound is a Pt(II)-based compound, the ratio of total moles of cyclodiene to moles of platinum is less than 3:1. | 2015-12-17 |
20150361113 | SILICONE COMPOUND AND A USE THEREOF - One of the purposes of the present invention is to provide a compound which is a polymerizable monomer having a specific number of silicon atoms and a specific number of fluorine atoms, has a higher purity, is suitable as an ophthalmic monomer, is well compatible with another (meth)acryl monomer, and provides a polymer having excellent hydrophilicity, anti-staining property and durability of mechanical strength and to provide a method for preparing the compound. The present invention provides a compound represented by the following formula (1). | 2015-12-17 |
20150361114 | Silicone Compound and a Use Thereof - The purpose is to provide a silicone compound which is well compatible with polymerizable silicone monomers and other polymerizable monomers to provide a polymer having high oxygen permeability, excellent hydrophilicity and anti-staining property, excellent dimension stability, and enough durability of mechanical strength not to deteriorate in a phosphate buffer solution. The other purpose is to provide a silicone compound having a high blocked terminal ratio and a high ratio of one specific structure and a method for preparing the silicone compound. The invention provides a compound represented by the following formula (1). | 2015-12-17 |
20150361115 | METHOD FOR PRODUCING ALKYL CHLOROSILANES BY WAY OF REARRANGEMENT REACTIONS - Alkyl chlorosilanes from the manufacture of dialkyldichlorosilanes are rearranged in continuous fashion to dialkyldichlorosilane by a rearrangement reaction in a moving bed reactor employing a solid alumina catalyst containing aluminum chloride, spent catalyst being continuously removed from the reactor. | 2015-12-17 |
20150361116 | NOVEL WATER-SOLUBLE COMPLEXING AGENTS AND CORRESPONDING LANTHANIDE COMPLEXES - The invention relates to complexing agents of formula (I): | 2015-12-17 |
20150361117 | PREPARATION OF A HYDROXYALKYL PHOSPHONIC ACID - The present invention is a process for converting a phosphonate to a hydroxyalkyl phosphonic acid comprising the step of contacting together water, the phosphonate, and a sulfonated or phosphonated heterogeneous catalyst under conditions sufficient to convert at least 50% of the phosphonate to the hydroxyalkyl phosphonic acid. The process of the present invention provides a way of preparing hydroxyalkyl phosphonic acids safely and economically, without corrosive effects. | 2015-12-17 |
20150361118 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLEFIN OLIGOMERIZATION USING THE SAME - The present invention relates to a ligand compound, a catalyst system for ethylene oligomerization, and a method for ethylene oligomerization using the same. The catalyst system for ethylene oligomerization according to the present invention not only has excellent catalytic activity but also shows more improved liquid olefin selectivity, and enables more effective preparation of an alpha-olefin through the oligomerization of ethylene because it is particularly possible to control the selectivity to 1-hexene or 1-octene. | 2015-12-17 |
20150361119 | COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY - The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. | 2015-12-17 |
20150361120 | MACROLIDE INHIBITORS OF mTOR - The present invention relates to new macrolide inhibitors of mTOR, pharmaceutical compositions thereof, and methods of use thereof. | 2015-12-17 |
20150361121 | METHOD OF PREPARING CHITIN NANOFIBERS - The present invention discloses a method of preparing chitin nanofibers. By increasing the saturated moisture content of chitin and instantaneously releasing the pressure under a high temperature and high pressure environment, water within the chitin micro-particles is quickly evaporated and thus generated a high vapor pressure. Consequently, the interaction in chitin fiber is broken, and therefore the chitin nanofibers are obtained. | 2015-12-17 |
20150361122 | Glycomimetics As Pseudomonas Aeruginosa Lectin Inhibitors - The present invention relates to fucose- and mannose-derived glycomimetics and their general use in prophylaxis or treatment of | 2015-12-17 |
20150361123 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF - A novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection is provided. The pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound has a good anti-HCV effect. | 2015-12-17 |
20150361124 | METHOD FOR THE SOLID-PHASE BASED SYNTHESIS OF PHOSPHATE-BRIDGED NUCLEOSIDE CONJUGATES - A method for producing phosphate-bridged nucleoside conjugates, in particular poly- or oligonucleosides. In the method, an immobilized cyclosaligenyl derivative of a nucleoside, nucleotide, poly- or oligonucleotide, poly- or oligonucleoside, or an analog thereof, is synthesized, and the subsequent reaction with a nucleophile yields the desired phosphate-bridged nucleoside conjugate, which may subsequently be released from the solid phase. | 2015-12-17 |
20150361125 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS - The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 2015-12-17 |
20150361126 | ANDROGEN RECEPTOR DOWN-REGULATING AGENTS AND USES THEREOF - The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR. | 2015-12-17 |
20150361127 | METHODS FOR ISOLATING BLOOD PRODUCTS FROM AN INTER-ALPHA INHIBITOR PROTEIN-DEPLETED BLOOD PRODUCT MATERIAL - Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (lαlp). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components. | 2015-12-17 |
20150361128 | METHODS OF USING ION EXCHANGE CHROMATOGRAPHY TO CONTROL LEVELS OF HIGH MANNOSE GLYCOFORMS - Provided are methods of using ion exchange based chromatography to control the levels of high mannose glycoforms in a glycoprotein sample, such as an antibody sample. The high mannose glycoforms can be removed from the sample or isolated and enriched. Also provided is a composition comprising a glycoprotein, such as an antibody, from which the high mannose glycoforms have been reduced or removed or isolated or enriched using an ion exchange based chromatography step. | 2015-12-17 |
20150361129 | METHODS FOR INCREASING THE CAPACITY OF FLOW-THROUGH PROCESSES - In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device. | 2015-12-17 |
20150361130 | Capture Purification Processes for Proteins Expressed in a Non-Mammalian System - Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided. | 2015-12-17 |
20150361131 | HIGH TEMPERATURE DEAD END ANTIBODY FILTRATION - The invention relates to a method of dead end filtration of a highly concentrated antibody containing solutions at a temperature above room temperature, wherein the filter flow rate is increased compared to filtration at a room temperature, the filter flow rate is kept constant and the yield increased compared to filtration at a room temperature. | 2015-12-17 |
20150361132 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2015-12-17 |
20150361133 | METHOD FOR PRODUCING GAMMA -GLUTAMYL-VALYL-GLYCINE CRYSTAL - The present invention provides a method for efficiently producing a γ-glutamyl-valyl-glycine crystal. Specifically, the present invention provides a method for producing a γ-glutamyl-valyl-glycine crystal, which includes the steps of: preparing a mixed solution of valyl-glycine or a salt thereof and γ-glutamyl-valyl-glycine, wherein the mixed solution contains valyl-glycine or the salt thereof in an amount of 20 mass % or more relative to the mass of γ-glutamyl-valyl-glycine; adjusting the amount of valyl-glycine or the salt thereof in the prepared mixed solution to 0.1 mass % or more and less than 20 mass % relative to the mass of γ-glutamyl-valyl-glycine to prepare a γ-glutamyl-valyl-glycine solution; and subjecting the γ-glutamyl-valyl-glycine solution to a crystallization procedure to produce the γ-glutamyl-valyl-glycine crystal. | 2015-12-17 |
20150361134 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 2015-12-17 |
20150361135 | POLYPEPTIDE SPECIFICALLY BINDING TO RARE EARTH NANOPARTICLES AND USE THEREOF - The present invention provides a polypeptide able to specifically bind to rare-earth nanoparticles and the use thereof. The polypeptide comprises an amino acid sequence shown by SEQ ID NO: 1 or analogues thereof. The present invention further provides a method for screening a polypeptide having the capacity of specifically binding to rare-earth nanoparticles. The present invention further provides a method for regulating and controlling the in vivo and in vitro autophagy and toxicity of the rare-earth upconversionnanophosphor material, comprising mixing and incubating the polypeptide specifically binding to rare-earth nanoparticles with rare-earth upconversion nanophosphor material, such that the polypeptide specifically binds to the nanophosphor material, wherein the rare-earth upconversion nanophosphor material comprises the rare earth, and the polypeptide specifically binding to rare-earth nanoparticles comprises the amino acid sequence shown by CTARSPWIC (RE-0, SEQ ID NO: 1) or analogues thereof. | 2015-12-17 |
20150361136 | NOVEL TRH BINDING SITE IN HUMAN CNS - The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterise the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders. | 2015-12-17 |
20150361137 | PEPTIDE INHIBITORS OF NICOTINIC ACETYLCHOLINE RECEPTOR - The present invention refers to biochemistry, namely to new peptide compounds having the ability to selectively block the muscle-type nicotinic acetylcholine receptor. The claimed compounds have common formula (I): X1-X2-X3-Pro-X4-Pro-X5 (SEQ ID NO: 54), where X1 is chosen within H, Ac—, Palm-; X2 is chosen within Trp, Tyr; X3 is chosen within Trp, Tyr; X4 is chosen within Lys, Orn, Dbu, Dpr, Arg; X5 is chosen within —OH, —NH | 2015-12-17 |
20150361138 | KISS1R RECEPTOR AGONIST COMPOUNDS AND USE THEREOF FOR INDUCING OVULATION IN MAMMALS - A KISS1R agonist peptide compound capable of inducing ovulation in a female mammal is provided. The compound is a pseudopeptide having the C-terminal sequence: -XaaΨ[Tz]Xaa2-Xaa3-Xaa4-NH | 2015-12-17 |
20150361139 | CRYSTALLINE FORM OF LINACLOTIDE - Linaclotide is a guanylate cyclase type C receptor (GCC) agonist used in the treatment of gastrointestinal disorders and conditions, including irritable bowel syndrome and chronic constipation. Crystalline form II of Linaclotide is prepared in high purity and yields and shows superior chemical stability in comparison to known crystal or amorphous forms of Linaclotide. A process for the purification of Linaclotide is also provided. | 2015-12-17 |
20150361140 | MITOCHONDRIAL TARGETING PEPTIDE - The present invention relates to a mitochondria targeting peptide, a fusion protein in which the peptide is bound to the carboxyl terminus of a protein transduction domain, a fusion protein in which the peptide is bound to the carboxyl terminus of a protein transduction domain and an antioxidant is bound to the carboxyl terminus of the peptide, an antioxidant composition and a composition for preventing or treating Parkinson's disease including the fusion protein in which the antioxidant is bound, a recombinant polynucleotide in which a polynucleotide coding a protein transduction domain, a polynucleotide coding the peptide, and a polynucleotide coding an antioxidant protein are sequentially bound, to an expression vector including the polynucleotide, and to a transformed host cell including the expression vector. | 2015-12-17 |
20150361141 | CRIMEAN-CONGO HAEMORRHAGIC FEVER VIRUS ANTIGENIC COMPOSITION - The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment. | 2015-12-17 |
20150361142 | VACCINE FOR PREVENTING PORCINE EDEMA DISEASE - A purpose is to provide a vaccine which can prevent porcine edema disease in farms where porcine edema disease is anticipated. Meeting this purpose is a vaccine that is a fusion protein in which Stx2eB and a polypeptide having a coiled-coil forming unit are joined or a multimer of the fusion protein, and by immunizing pigs with this vaccine, it is possible to induce potent neutralizing antibodies and to defend against the onset of porcine edema disease. | 2015-12-17 |
20150361143 | METHOD FOR PRODUCING HIGH-QUALITY RECOMBINANT ALLERGENS IN A PLANT - A method for producing a recombinant protein in a plant, in particular a tobacco plant, preferably | 2015-12-17 |
20150361144 | POLYPEPTIDE POROUS BODY AND METHOD FOR PRODUCING SAME - A polypeptide porous body of the present invention is a porous body of a polypeptide derived from spider silk proteins. The polypeptide includes a water-insoluble polypeptide. The polypeptide porous body has an apparent density of 0.1 g/cm | 2015-12-17 |
20150361145 | FLUORESCENT FUSION PROTEIN - A fluorescent fusion protein is provided. The fluorescent fusion protein of the invention comprises a first fluorescent protein with first emission wavelength, a second fluorescent protein with second excitation wavelength and second emission wavelength, and a linker peptide linking the first fusion protein and the second fusion protein, wherein the first emission wavelength overlaps the second excitation wavelength so that the second fluorescent protein exhibits the second emission wavelength after receiving energy. The fluorescent fusion protein of the invention exhibits a stronger fluorescence in the absence of bilivirdin (BV). | 2015-12-17 |
20150361146 | MG53 Mutant, Methods of Mutation and Use Thereof - Disclosed in the present invention is a MG53 mutant, wherein any one or two or more of 7 cysteines in the RING domain at the N-terminal of MG53 are mutated into mutations of non-polar amino acids. The MG53 mutant has preventive/therapeutic effects and uses in the protection of the heart, and the treatment of heart diseases caused by cell death, while avoiding the side effects caused by MG53 such as insulin resistance, obesity, and diabetes etc. | 2015-12-17 |
20150361147 | NOVEL CANCER ANTIGEN EEF2 - The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject. | 2015-12-17 |
20150361148 | AMYLOID BETA EXPRESSION CONSTRUCTS AND USES THEREFOR - Disclosed are yeast expression constructs encoding a polypeptide containing a signal sequence, a Golgi-directing pro sequence, and a human amyloid beta protein, and mammalian expression constructs encoding a polypeptide containing a selected signal sequence and a human amyloid beta protein. Also disclosed are methods of screening cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease. | 2015-12-17 |
20150361149 | METHOD FOR DEVELOPMENT OF A PEPTIDE BUILDING BLOCK USEFUL FOR DE NOVO PROTEIN DESIGN - The present invention relates to a top-down symmetric deconstruction approach which provides a novel alternative means to successfully identify a useful polypeptide “building block” for subsequent “bottom-up” de novo design of target protein architecture. The present invention also pertains to a novel peptides isolated by top-down symmetric deconstruction which may be useful for design or directed evolution of novel proteins with novel functionalities. | 2015-12-17 |
20150361150 | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL STROMAL TUMOR (GIST) - The invention features nucleic acid constructs encoding chimeric immunoreceptors (CIRs) that are useful for treating a KIT+ associated disease in patients. In general, the CIRs contain an extracellular domain (e.g., a KIT-ligand (KL) or stem cell factor (SCF)) which interacts with and destroys KIT+ tumor cells, a transmembrane domain, and a cytoplasmic domain for mediating T cell activation (e.g., CD3 zeta and/or the domain of CD28). The invention also features the use of the nucleic acid constructs and/or host cells expressing CIRs in the treatment of a KIT+ associated disease, in particular gastrointestinal stromal tumor (GIST). | 2015-12-17 |
20150361151 | MACROPHAGE ACTIVATING FACTOR FOR PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising macrophage activating factor (MAF) and method of producing same, particularly to MAF compositions essentially devoid of glycosidase enzymes. The compositions of the present invention and pharmaceutical compositions comprising same are particularly suitable for intravenous administration. | 2015-12-17 |
20150361152 | MONOMERIC CXCL121 PEPTIDE AND METHODS OF SYNTHESIS AND USE THEREOF - The present invention provides a CXCL12 | 2015-12-17 |
20150361153 | INSULIN ANALOGUES WITH CHLORINATED AMINO ACIDS AND NUCLEIC ACIDS ENCODING THE SAME - An insulin analogue comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The chlorinated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration. | 2015-12-17 |
20150361154 | THERAPEUTIC AGENTS, COMPOSITIONS, AND METHODS FOR GLYCEMIC CONTROL - The present invention relates in part to insulin proteins and pharmaceutical compositions having therapeutic advantages. | 2015-12-17 |
20150361155 | PD-L1 AND PD-L2-BASED FUSION PROTEINS AND USES THEREOF - Provided are fusion proteins comprising a first domain and a second domain, wherein the first domain comprises a polypeptide that binds to and triggers PD-1 and the second domain comprises a polypeptide that binds to and triggers a TRAIL receptor or Fas. In some embodiments, the polypeptide that binds to and triggers PD-1 comprises at least a portion of the extracellular domain of PD-L1 or PD-L2 and the second domain comprises at least a portion of the extracellular domain of TRAIL or Fas ligand. Also provided are methods for treating autoimmune, alloimmune or inflammatory diseases, and methods for treating cancer, using the fusion proteins. | 2015-12-17 |
20150361156 | METHODS OF MODULATING GABAERGIC INHIBITORY SYNAPSE FORMATION AND FUNCTION - The present technology relates to methods of modulating the number of GABAergic synapses between at least two neurons. These methods include contacting at least one of the neurons with a PlexinB agonist or a nucleic acid molecule encoding a PlexinB agonist, such as a composition including a Sema4D polypeptide or an extracellular fragment thereof, or a nucleic acid molecule encoding the Sema4D polypeptide or extracellular fragment thereof. The present technology also relates to methods of modulating neuronal activity in the central nervous system or peripheral nervous system of a subject in need thereof by modulating the number of GABAergic synapses between at least two neurons. The present technology further relates to methods of treating a neuro logical disorder that would benefit from modulating neuronal activity in the central nervous system or peripheral nervous system of a subject in need thereof. | 2015-12-17 |
20150361157 | SGP130/FC DIMERS - Described are polypeptide dimers comprising two soluble gp130 molecules wherein each of said molecules is fused to an Fc domain of an IgG1 protein and wherein the hinge region of the Fc domain is modified resulting in advantageous properties of the dimer. In a particularly preferred embodiment, the hinge region comprises the amino acid sequence motif Ala | 2015-12-17 |
20150361158 | Optimized Factor VIII Gene - The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. | 2015-12-17 |
20150361159 | FIBRONECTIN BASED SCAFFOLD PROTEINS - Fibronectin type III ( | 2015-12-17 |
20150361160 | BROADLY NEUTRALIZING ANTIBODY AND USES THEREOF - The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC | 2015-12-17 |
20150361161 | ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE - Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10. | 2015-12-17 |
20150361162 | NUCLEOTIDE AND AMINO ACID SEQUENCES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to genes identified from human chromosome 12q23-qter, which are associated with various diseases, including asthma. The invention also relates to the nucleotide sequences of these genes, isolated nucleic acids comprising these nucleotide sequences, and isolated polypeptides or peptides encoded thereby. The invention further relates to vectors and host cells comprising the disclosed nucleotide sequences, or fragments thereof, as well as antibodies that bind to the encoded polypeptides or peptides. Also related are ligands that modulate the activity of the disclosed genes or gene products. In addition, the invention relates to methods and compositions employing the disclosed nucleic acids, polypeptides or peptides, antibodies, and/or ligands for use in diagnostics and therapeutics for asthma and other diseases. | 2015-12-17 |
20150361163 | METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING SICKLE-CELL DISEASE - In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sickle-cell disease or one or more complications associated with sickle-cell disease. | 2015-12-17 |
20150361164 | HUMANIZED ANTl-HMGB1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF - The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof. | 2015-12-17 |
20150361165 | MFAP4 BINDING ANTIBODIES BLOCKING THE INTERACTION BETWEEN MFAP4 AND INTEGRIN RECEPTORS - Microfibrillar-associated protein 4 (MFAP4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels. The provided antibodies block the interaction between MF AP4 and integrin receptors. | 2015-12-17 |
20150361166 | DIPEPTIDE-REPEAT PROTEINS AS THERAPEUTIC TARGET IN NEURODEGENERATIVE DISEASES WITH HEXANUCLEOTIDE REPEAT EXPANSION - The present invention relates to a method of detecting a disease characterized by an expansion of genomic hexanucleotide repeats as well as polypeptides of said hexanucleotide repeats, ligands specifically binding to the polypeptide, methods of identifying an inhibitor preventing the expression and/or aggregation of said polypeptide. | 2015-12-17 |
20150361167 | ANTIBODIES DIRECTED AGAINST PYROGLUTAMATE MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1 N1PE) - Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE). | 2015-12-17 |
20150361168 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein—(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 2015-12-17 |